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overall survival in multivariate analysis. As to progression-
free survival, disease-free interval, PALN size, and upfront 
radiotherapy (or chemoradiotherapy) were significant 
prognostic factors in multivariate analysis. Acute grade 3 
gastrointestinal and hematologic toxicities developed in 3 
patients. 
 
Conclusion: For isolated PALN recurrence of cervical cancer, 
upfront radiotherapy (or chemoradiotherapy) should be 
considered as a salvage treatment, especially in patients with 
long disease-free interval. 
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Purpose or Objective: To present the long term outcomes 
and results of the clinical audit of cervical cancer cases 
treated at our cancer centre in the year 2010. 
 
Material and Methods: A clinical audit of case records of 
cervical cancer treated at our centre in the year 2010 was 
analysed. Out of the 306 patients evaluated for Cervical 
Cancer, case records for demographics, treatment 
methodology, long term toxicity and survival data was 
analysed using the SPSS. The variables were compared using 
the Chi-square test, the survival by Log-Rank test. 
 
Results: Out of a total of 306 patients with a median age 
group of 50 years (range-30-80) evaluated for various 
symptoms pertaining to cervical cancer, 204 underwent 
concurrent chemoradiation and 102 patients received only 
radiation alone. In the total cohort, FIGO stage grouping was 
stage II in 36% (n=111), stage III in 56% (n=172) and stage IVA 
in the remaining. Radiation was delivered to a dose of 75Gy 
to point A, external beam radiotherapy (dose of 45-50Gy) 
being delivered predominantly on the Telecobalt and 
followed with low dose rate brachytherapy. Cisplatin based 
concurrent chemotherapy was delivered as weekly at a dose 
of 40 mg/sqm in 76% of the patients, while in the rest it was 
delivered as three-weekly regimen. In the weekly 
chemotherapy arm, 70% of them received atleast 4 cycles. 
Median overall treatment time (OTT) was 8.4 weeks (40-95 
days). At a median follow up of 36 months, 5 year overall 
survival in the entire cohort was 30%. The OS in the 
concurrent chemo radiation arm was better (34% Vs. 29%, 
p=0.036). The OS in the two chemotherapy arms did not show 
a difference (log rank, p=0.46). The survival difference 
between the two stage groups demonstrated a superior 
outcome in patients with stage II (40% vs 32%, p=<0.05). 
Multivariate analysis showed stage, type of chemotherapy 
and overall treatment (OTT) time were significant for OS. 
Acute hematologic, GI, GU and skin toxicity was higher in 
chemoradiation arm. Difference in long term toxicity 
between the two treatment arms was not statistically 
significant. 
 
Conclusion: Our clinical audit of cervical cancer cases 
treated at our cancer centre, although demonstrates slight 
inferior survival outcome compared to available literature, 
might be accounted for the lower Point A dose, longer overall 
treatment time, and suboptimal chemotherapy dose. These 
factors have been taken care in our current clinical practice. 
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Purpose or Objective: Endometrial cancer (EC) is the most 
common gynecologic malignancy in developed countries, 
affecting 40,000 women/year. Recent studies have shown the 
therapeutic benefit of pelvic lymphnode dissection in order 
to determine the extent of desease and establish adiuvant 
therapies. Several trials have also shown that adiuvant 
radiotherapy(RT) in early stage EC reduces the risk of local 
recurrence without improving overall survival (OS). However 
the role of both lymphnode dissection and adiuvant RT in 
high risk early stage EC is not clearly defined. The aim of our 
retrospective study is to evaluate the validity of 
linfadenectomy with intravaginal brachiterapy (IVRT) as 
therapeutic option in high risk early stage EC, compare it 
with adjuvant external beam radiotherapy (EBRT) and 
determine which one determine the best results in terms of 
Reccurrence Free Survival (RFS) and OS. 
 
Material and Methods: Were evalueted 85 patients with EC 
treated between January 2007 and January 2012 with 36 
months of follow-up. Of these, 47 had low risk early stage 
(G1 with myometrial infiltration less than 50% or G2 with 
myometrial infiltration less than one third ) treated with 
bilateral histerosalpingovariectomy without any adjuvant 
therapy; 38 were patients with high risk early stage (G1 with 
more than 50% of myometrial invasion, G2 with more than 
one third of myometrial infltration and G3) treated with 
bilateral hysterosalpingo-oophorectomy and then submitted 
to pelvic lymphadenectomy (n. 22 pts) plus IVRT or EBRT (n. 
16 pts) based on age, comorbidities, tumor grade, histotype, 
tumor size, presence of lymphovascular invasion space, depth 
or myometrial infiltration. 
 
Results: The recurrence rate was respectively of 4% (n.2 pts) 
among the low risk patients with a RFS of 96% and of 19% 
(n.11 pts) among the high risk patients with a RFS of 81%. 
Considering the high risk group, the 45% of recurrence 
(n.5pts) occurred among patients treated with EBRT and the 
55%(n.6pts) among those who received lymphadenectomy 
with IVRT. The mortality rate was respectively 0% (n.0 pts) 
among patients treated with EBRT and 0% (n.0 pts) among 
those who received lymphadenectomy with IVRT. 
 
Conclusion: Our study shows that in high risk early stage EC 
there is no significant difference in terms of RFS among 
patients who received pelvic lymphadenectomy with IVRT 
and those which had been treated with EBRT. There was also 
no statistically significant difference for OS between the two 
groups. 
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Purpose or Objective: To determine the maximum tolerated 
dose (MTD) and effectiveness of weekly PTX plus DDP 
concurrent with whole pelvic irradiation in Chinese women 
with locally advanced cervical cancer. 
 
Material and Methods: Between November 2008 and March 
2015, a total of 36 patients with primarycervical cancer 
cervical cancer, FIGO stage IB1 to IIIB, confirmed by 
histology, negative para-aortic lymph nodes were enrolled 
into this phase I / II trial. Chemotherapy agents were 
